A Single-Case Experimental Design to Study the Combination of Cognitive-Behavioral Therapy and Pharmacotherapy for Smoking Cessation

Bijan Pirnia1,2*, Maryam Akhondi3, Kambiz Pirnia4, Parastoo Malekanmehr5, Sima Farzaneh6, Kosar Deilam1, Mozhdeh Bazargan7, Leila Komeilizadeh8, Alireza Zahiroddin9

Abstract
Bupropion is an anti-depressant drug which is a category of aminoketones. It is a norepinephrine-dopamine inhibitor, which is considered as a nicotine antagonist and is effective in smoking cessation. The patient was a single 21-year-old girl and she was a student and had been referred to Bijan Addiction Treatment Clinic in Tehran with a complaint of chronic smoking. After a period of abstinence from consumption, she experienced anhedonia syndrome and recurrence of consumption. Data were collected from October to February 2016. We used a reversal (ABAB) design with multiple baselines, in which A was the baseline and B was the intervention phase. The entire course was 12 weeks, during which bupropion was presented. In the baseline A1 and A2, only bupropion was presented, and in B1 and B2 stages, in addition to bupropion, cognitive-behavioral therapy (CBT) was also presented. Cigarette Cravings Index and Heaviness of Smoking Index (HSI) were completed at 24 time points by the subjects. Data were analyzed by semi-parametric test of generalized estimation equation. Data analysis indicated that the addition of CBT to bupropion was associated with a significant reduction in the scores of HSI and Cigarette Cravings Index compared to bupropion alone (P<0.01). These findings can reflect the role of complementary psychological interventions in the treatment of addiction and suggest a promising perspective in linking biological and cognitive indices in response to the addiction challenge.

Keywords: Cognitive-behavioral therapy, Bupropion, Smoking cessation

Introduction
A report by the World Health Organization (WHO) indicates that smoking is a risk factor for six of every eight deaths worldwide. Tobacco use is a risk factor for many chronic diseases such as cancer, pulmonary diseases, and cardiovascular diseases, and is one of the greatest preventable causes of premature death worldwide. However, in general, it has been shown that smoking is an ineffective coping strategy which causes undesirable outcomes. Medications such as nicotine replacement therapy (NRT), varenicline, bupropion, cytosine, and behavioral support increase the success rate of smoking cessation (1).

Bupropion (Wellbutrin and Zyban) is a category of aminoketones and is an anti-depressant drug that is effective in smoking cessation (2). On the other hand, studies have shown that bupropion along with cognitive-behavioral therapy is effective in treating smoking (3).

Previous studies have shown that the combination of pharmacotherapy and behavioral interventions increases the likelihood of success in smoking cessation (1). The results of the meta-analysis by Stead et al (4) indicated the effectiveness of the combination of pharmacotherapy and behavioral support.

On the other hand, nicotine dependency and depression have high comorbidity. A possible mechanism is that nicotine reduces neurobiological disorders associated with depression. For example, the activity of corticostriatal circuitry is intensified by nicotine, while this pathway is impaired in people with depression (5).

Studies have shown that avoiding tobacco use reduces the response to non-pharmacological therapies or anhedonia (6). Anhedonia is a tobacco withdrawal syndrome after smoking cessation. The experience of anhedonia is known to be a factor in starting to consume and continue smoking in adults (7). Considering the therapeutic
effects of bupropion on depression, as well as the role of cognitive-behavioral therapy in reducing depression and helping to avoid smoking, the complementary role of the two treatments is important and will have clinical implications.

Despite the research evidence, a similar study has not been conducted in Iranian society. Therefore, the present study aimed at assessing the role of supportive cognitive-behavioral therapy (CBT) in the effectiveness of bupropion in smoking cessation.

Case Report

In a single-case experimental study with multiple baselines in the form of a reversal $A_1B_1A_2B_2$ design (TCTR20180329004), between October 2016 and April 2017, a 21-year-old single female student with a complaint of high cigarette smoking was selected using a respondent-driven sampling method (8). After a 3-month period of avoiding consumption, she experienced anhedonia syndrome and recurrence of consumption. We used a reversal $A_1B_1A_2B_2$ design (9), in baseline $A_1$ (3 sessions) and $A_2$ (3 sessions) only bupropion was presented, and in $B_1$ (4 sessions) and $B_2$ (2 sessions), in addition to bupropion, CBT (weekly sessions of 60 minutes) was presented. The entire period was 12 weeks, throughout which Bupropion treatment was offered. We used 150 mg bupropion (Wellbutrin Extended-release, Abidi Pharmaceutical Company, Tehran, Iran) twice a day (once in the first 3 days) for 12 weeks. The basics of CBT treatment were presented in the main topics of the dangers of smoking, craving, coping strategies, the difficulties and benefits of treatment and relapse prevention. The Cigarette Craving Index was considered as primary outcome and the Heaviness of Smoking Index (HSI) as secondary outcome which were completed twice a week at 24 time points by the subject and the data were analyzed by semi-parametric test of generalized estimation equation (10) (IBM Corp., Armonk, NY, USA).

Distribution of the scores of Craving Index is presented in Figure 1. The average craving score for each session at the first baseline phase is 13.3. This amount decreased to 6.75 in the first intervention phase. In the second baseline phase, the craving scores increased to 11.3. In the second intervention phase, the score dropped to 3.5. The difference between baseline and intervention scores was significant based on the results of the generalized estimation equation ($P<0.01$). Moreover, the difference in HSI between the baseline and the intervention was significant ($P<0.01$, Figure 2). Addition of CBT to bupropion has been associated with a significant reduction in craving compared to bupropion treatment alone.

Discussion

The results of this study showed that adding CBT to bupropion was associated with a reduction in the scores of the heaviness of smoking and smoking craving. These findings support previous studies in the general population. Along with our results, the study by Loreto et al (3) showed that the addition of CBT to bupropion and nicotine patch has been associated with a reduction in
the heaviness of smoking rate and the success of treatment in females. In addition, a systematic study by Stead et al. (11), including 53 studies with a total of more than 25,000 participants, showed that the combination of drug therapy and behavioral support increases the overall success of smoking cessation compared to the normal care. On the other hand, the study by Jiang et al. (12) showed that the addition of bupropion to counseling was accompanied by a significant reduction in smoking compared to counseling alone.

On the other hand, the results of the study by Laude et al. (13) showed that although the addition of CBT to bupropion is beneficial, prolonging CBT from 26 to 48 weeks cannot improve the long-term avoidance of smoking.

The findings of this study showed that the addition of CBT to bupropion was associated with a significant reduction in the scores of HSI and Cigarette Craving Index compared to bupropion alone. These findings indicate the role of psychotherapy along with drug interventions in avoiding smoking and can provide a promising perspective on linking biological and cognitive indices in response to the addiction challenge.

**Conflict of Interests**

None declared.

**Ethical Issues**

All stages of the study were based on the latest version of the Declaration of Helsinki, and written consent was obtained from the patient.

**Financial Support**

None.

**References**


10. Pirnia B, Pirnia K, Aghajanpoor M, Mardan F, Zahiroddin...


